Calypte Only Company with Full Menu of Tests.

noch kommt ihr zu 0,20$ raus....

heute abend allerdings wohl nicht mehr:

Support/Resistance
Type Value Conf.
resist. 0.31 2
resist. 0.29 2
resist. 0.28 3
resist. 0.25 10
resist. 0.24 4
resist. 0.22 6
resist. 0.21 4
supp 0.20 15
supp 0.19 20
supp 0.18 10
supp 0.17 16
supp 0.16 46
supp 0.15 6
supp 0.13 12
 

Time & Sales  
Price Size    Exch Time
0.21 2500    NLS 15:58:01
0.21 5100    AMX 15:57:58
0.21 100    PAC 15:57:52
0.21 1900    PAC 15:57:52
0.20 10000    NLS 15:57:47
0.21 10000    AMX 15:55:09
0.20 900    NSX 15:47:48
0.20 900    PAC 15:47:48
0.21 20000    NLS 15:42:13
0.21 100    PAC 15:41:34
0.21 100    PAC 15:41:34
0.21 100    PAC 15:41:34
0.21 100    PAC 15:41:34
0.21 100    PAC 15:41:34
0.21 100    PAC 15:41:34
0.21 100    PAC 15:41:34
0.21 100    PAC 15:41:34
0.21 100    PAC 15:41:34
0.21 100    PAC 15:41:34
0.21 100    PAC 15:41:34
0.21 100    PAC 15:41:34
0.21 100    PAC 15:41:34
0.21 100    PAC 15:41:34
0.21 100    PAC 15:41:34
0.21 100    PAC 15:41:34
0.21 100    PAC 15:41:34
0.21 100    PAC 15:41:34
0.21 100    PAC 15:41:34
0.21 100    PAC 15:41:34
0.21 100    PAC 15:41:34

durchschnittshandelskurs: 0.2113$

als low gab es am 06.02 sogar schon die 0.1901$...  

 

Lucky ist angeblich vor 6 Jahren zu einem Kurs von über 100 Euro eingestiegen!
Die Gebühren eines Verkaufs dürften den Wert seiner Position bei weitem übersteigen ;-)
 

Das kann ich ja fast gar nicht glauben. Wenn dem so wäre, hilft da wirklich nur noch ein Wunder. Ich wünsch dem Lucky mal, dass das Wunder wirklich eintritt.
Grüße, ZN  

ich habe meine meinungen IMMER anhand von zahlen und fakten untermauert. dafür wurde ich dann entsprechen hier im board behandelt. sogar von den mods.

 

aber ich bin immer noch da...undjetzt gibt es dafür kein mitleid mehr, sondern nur schadenfreude...besonders für brokersince1994 und kade, dei 2 gefährlichsten subjekte hier im board

 

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

 

bei der gegenwärtigen lage will ich nicht hoffen, dass du dein blaues wunder erlebst.

mensch junge, wenn du noch kohle retten willst oder kannst: dann jetzt!!!

was soll denn deiner meinung nach kommen?

glaubst du im ernst an großaufträge für ein firma mit weniger als 15 mann? das ist kein konstruktionsbüro! die müssen produzieren!!! wie sollen sie das??????

die produktionsstätten sind doch dicht ind en usa!!! gibte es schon neue in china oder thailand? - nein!!!!! - ansonsten hätten sie keine 15 mann, sondern mehr!!!

das alte operative geschäft ist verkauft/verschenkt. die lagerprodukte sind weitestgehend leerverkauft!!!

junge, junge, komm zu dir!!!!!!!! da wird nur noch verwaltet und der aktienfluß gelenkt, sonst nichts!!!

für wirklich produktionen brauche  die VIIIIEEEELLL kohle und die gibt es nur durch massive aktienverkäufe mit anschließendem RS!!

denk drüber nach!  

kurz bevor das delisting angedroht wird, ziehen sie den kurs mit geschickt lancierten meldungen nochmal kräftig nach oben!!!!

wenn die meldungen nicht gekommen wären + das drohende delisting, dann wäret ihr jetzt bei 0,10$.

was hier baläuft ist doch abzocke vom aller asozialsten.

ich sage dir: caly wusste, dass da in kürze was wg. dem amex-lisitng kommen würde...  

Bezugnehmend auf deine Aussage........ nur 15 Mitarbeier,
da kann bei dieser Anzahl vom Mitarbeiter, bei einen großen Auftrag, Calypte den Auftrag nicht ausführen.....

FALSCH JOELU; WEIST DU AUCH WARUM ? lesen.....
Calypte Launches International Manufacturing Initiative of its Rapid HIV Type 1 and HIV Type 2 Tests
Announces License and Supply Agreement with Adaltis, Inc. Memorandum of Understanding Signed for Initial Manufacturing of HIV-1/2 Rapid Tests in Thailand
ALAMEDA, Calif., Apr 1, 2004 /PRNewswire-FirstCall via COMTEX/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT) a company engaged in developing rapid tests for HIV diagnosis and the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot supplemental test, today announced that it has entered into an agreement with Adaltis, Inc. to license and supply certain peptides to Calypte that are owned by Adaltis for the use in the Company's immunodiagnostic assays. The first application for the peptides will be in the Company's HIV rapid diagnostic tests currently under development.

The agreement provides Calypte with the supply of key, patented HIV-Type 1 and HIV-Type 2 (" HIV-1/2" ) peptides by Adaltis. Calypte's non-exclusive license to Adaltis' peptide sequences provides the Company total freedom to operate throughout the world, with the exception of Canada, where Calypte would work with Adaltis in its home territory. Calypte is licensing the right to market and sell the peptides as part of the development of its rapid HIV diagnostic test products.

Dr. J. Richard George, President and CEO of Calypte stated, " We have used the Adaltis HIV-1/2 peptides in the field trials of our rapid tests in Thailand. Their consistency provides the foundation necessary to achieve the high levels of performance we require for both specificity (false negatives) and sensitivity (false positives). Our field trials have included our blood rapid HIV-1/2 test for which we filed an Investigational Device Exemption Application (IDE) in the US last November, as well as our urine rapid HIV-1/2 test. We have also tested the product in house with other fluids and are pleased with the initial results from both a specificity and sensitivity perspective and are planning to include this additional product in our upcoming field trials later this month."

Dr. George added, " In the community of like sciences, we were encouraged to see that OraSure received FDA approval for their laboratory based rapid oral fluid test for HIV-1. Once our non-laboratory based rapid tests are out of development and into production, we initially plan to distribute them outside the United States. We believe that Calypte's products will soon have world appeal, and after we have introduced our tests internationally, we expect to file for FDA approval for marketing in the US as well. However, our current focus is Sub-Saharan Africa and the " next wave" emerging HIV epidemic countries where the problem is more widespread -- including, China and Russia."

Tony Cataldo, Executive Chairman of Calypte stated, " As Calypte pursues the development of its rapid HIV-1/2 tests, we believe we are now far enough along in our development to begin finalizing the necessary agreements and to start transferring the technology to commercial scale manufacturing. The largest markets in the world are the emerging markets and we believe we are now well positioned to serve those markets. "

Calypte currently has a non-exclusive worldwide distribution agreement with Adaltis Inc. of Montreal, Canada for the distribution of Calypte's serum HIV-1 Western Blot test.

First International Manufacturing Initiative in Thailand

Calypte is preparing for its first foreign manufacturing technology transfer and today also announced that it has signed a Memorandum of Understanding with Thailand-based Pacific Biotech Co., Ltd. to act as Calypte's initial international manufacturer for both its urine and blood rapid tests. Manufacturing will be located at the Pacific Biotech facility in Phetchaboon, Thailand and a formal agreement is expected to be finalized around the middle of April.

Commenting on this arrangement, Dr. George stated, " I have been familiar with the capabilities of Pacific Biotech for several years, and have had past personal experience with them as an ISO 9001 certified contract manufacturer for rapid assays. Our recent audit of their facilities and quality systems tells me that they are an experienced and quality-minded organization that is eminently qualified to manage the manufacturing task ahead of them."

Ninlawan Pichayayothin, President of Pacific Biotech, stated, " The technologies and quality systems involved in this project are very familiar to us. We are confident that we can manufacture the Calypte tests at our facility in both the quality and quantity demanded."

Separately, Calypte confirmed that it continues its focus on China, which the Company believes will be its largest market. Beijing Calypte Biomedical Technology Ltd., the Company's joint venture with Marr Technologies Limited, Calypte's business partner and affiliate of Marr Technologies BV, which owns 28% of Calypte's common stock, has begun negotiations that are expected to lead to a manufacturing joint venture in China that will be controlled by Beijing Calypte. The Company is optimistic that this manufacturing relationship could facilitate a quick regulatory approval process in China.

About Adaltis:

Adaltis Inc. is a privately held company headquartered in Montreal, Canada, and in addition to its Canadian operations, operates its own affiliates in the USA, Italy and Germany, as well as an extensive network of over 60 sub-distributors around the world.

About Pacific Biotech:

Pacific Biotech manufactures high quality diagnostic products to serve the healthcare market world wide on both an OEM basis and under its own brand. It has built a strong reputation for premium quality product and superb customer services for over a decade. Pacific Biotech products and services meet the Thai FDA compliance standards and ISO9001. With the strong support from the Board of Investment and National Science and Technology Development Agency, Pacific Biotech is a model of cooperation between the government and private sectors in promoting the development of a Thai biotechnology industry. Pacific Biotech's products are based on rapid immunochromatographic technologies, and include tests for reproductive hormones, drugs of abuse, and markers of infectious disease.


Danke fürs lesen,Lucky
 

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

 

» Clients
» Products
» Press Releases
» Photo Gallery
» Corporate Counsel
» Contact Information  
Press Releases  
 
Press Release to the U.S. Department of Commerce, January 11, 2006:
Joseph and Gionis, LLC, announce:

 
First in the World: Over-the-Counter (OTC) Oral HIV Test.

Joseph and Gionis is the first firm world-wide to obtain the first-ever over-the-counter (OTC) approval for an oral test swab HIV test kit for general sale and public use. The oral swab test accuracy is 99.8% and results are obtained in 20 minutes. The oral HIV test was approved in the United Arab Emirates. Joseph and Gionis has the Exclusive Distributor rights for the Calypte Aware OTC Oral HIV Test Kit for 22 Middle East countries.

 

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

 

alle die mit Caly zusammenarbeiten sind Verbrecher und auch die 15 Leute von Caly sind Verbrecher stimmts?

Einfach mal über den Tellerrand sehen an Weitsicht fehlt es bei manchen hier.

Ihr wird euch noch wundern, Kameraden

Lucky  

hat er hier http://www.ariva.de/board/217367?pnr=2370698#jump2370698 behauptet und wenn ich mir den Chart anschaue muß er rund 132 Euro bezahlt haben :o)
Ob man's glaubt steht natürlich auf einem anderen Papier ;-)  

1. The HIV oral rapid test over the counter approval in the UAE, the first in the world, occurring with Calypte.

2. News any day to come from China regarding a pending application to manufacture and sell the HIV oral rapd test there, which is most likely following.

3. News to come from Africa distributors what is occurring with trials there, as well as sales to those in countries already approved.

4. News as to the amount of sales at the Arab Health Conference which just ended last week.

5. News as to progress with approvals in the Philipines.

6. News as to approvals in India.

7. News as to sales in Hong Kong and the Asian region.

8. News as to advancements in approval and sales in Russia.

9. News as to approval and sales in Brazil.

10. News as to the continued ramping in BED incident sales.

11. News as to the new BED incident test.

I believe any and all of the above are the reasons for accumulation, not a reverse split

Remember, the company expected to be at " break even point by the end of this year.
 

mit ADALTIS vom "ALAMEDA, Calif., Apr 1, 2004", also fast 2 jahre alt ist und das die umsätze bisger NUR RÜCKLÄUFIG waren.

Fakt ist auch das die q-zahlen bisher in keinem einzigen quartal irgendwie rückschlüsse zuliessen, dass sich auch nur IRGENDETWAS bei caly zur umsatzsteigerung hinbewegt.

seit dem 01.04.2004 sind sage und schreibe 7 (in worten: SIEBEN!!!) quartale vergangen, ohne dass sich auch nur irgendetwas am umsatz getan hätte, was man dieser ominösen liason mit ADALTIS zuschreiben könnte.

FAkt ist auch, dass caly im grunde kein amex ist und dieses listing nur duch die hintertüre erschlichen hat, weil die mk damals mal 50.000.000$ betrug!!!! schau dir mal die kriterien an, habe mich aber vor 2 jahren schon darüber ausgelassen: WEDER durch den kurs (3 monate über 1$) noch über die wirtschaftlichkeitsanforderungen (gewisse größe an gewinn bzw. umsatz) wurde das listing erreicht!

fakt ist auch dass caly im mai letzten jahres 68% der belegschaft wegen mangelndem geschäftserfolg entlassen musste und auch keine kredite mehr bekommt. geld bekommt caly nur noch über die ausgabe von optionen, die vom optionnehmer dann SOFORT OHNE HALTEFRIST liquidiert werden können!  

 

Calypte Supports State of the Union Address HIV/AIDS Initiative

Company Offering Oral Fluid Over-the-Counter HIV-1/2 Rapid Diagnostic Test Internationally and HIV-1 Incidence Test World-wide LAKE OSWEGO, Ore., Feb 07, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Calypte Biomedical Corporation (Amex: HIV) today announced its support for President George W. Bush's proposal in his recent State of the Union address of an initiative to increase efforts to prevent, treat and ultimately defeat HIV/AIDS. The initiative proposes to distribute rapid HIV tests in areas of the country with the highest rates of newly discovered cases and in the areas having the highest numbers of undetected cases. Distinguishing recent from longer term HIV infection helps define incidence of HIV in a population. The Calypte HIV-1 BED Incidence EIA, a test originally developed by the Centers for Disease Control (CDC), is used in laboratories in the US and world-wide in the evaluation of recent HIV infection. This test is used in population incidence estimates to assist in prevention programs, targeting of educational and treatment resources, monitoring and evaluation and identifying high-risk cohorts for prevention research, including vaccine trials. The CDC and other surveillance laboratories are evaluating recent infections using the Calypte HIV-1 BED Incidence EIA in countries like China, Thailand, Vietnam, Brazil and South Africa. Calypte's Incidence Test also allows Dried Blood Spots to be evaluated. Testing and counseling of persons at risk for HIV infection and subsequent treatment of infected individuals remains a primary tool to curb transmission of the virus. Calypte has developed HIV-1/2 Rapid Tests for use in countries in Africa and Asia that are hardest hit by the HIV pandemic. The Calypte AWARE(TM) HIV-1/2 BSP antibody test uses finger stick blood in an easy to use dipstick format. The Calypte AWARE HIV-1/2 OMT test uses oral fluid as an alternative to blood. An over-the-counter (OTC) version of this test has recently been introduced into the Middle East. These inexpensive tests have demonstrated high accuracy in the target areas where increased testing is needed. Roger Gale, Calypte's Chairman and Chief Executive Officer commented, "Calypte is proud to be participating in the war against HIV/AIDS in such a meaningful and timely way. Our testing products are on the cutting edge for Public Health HIV surveillance with the Calypte HIV-1 BED Incidence EIA and for diagnosis with the Calypte AWARE HIV-1/2 Rapid Tests, now suitable for both the professional market and, in Oral form, for the OTC market." About Calypte Biomedical: Calypte Biomedical Corporation is a US-based healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases. Calypte specializes in novel tests such as the HIV-1 BED Incidence EIA and is engaged in developing and commercializing new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases, several of which do not require blood samples. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases. Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB/A (No. 2) for the year ended December 31, 2004 and its subsequent filings with the SEC. Company Contact:                         Investor Relations Contact:    Theodore R Gwin, Chief Financial Officer Tim Clemensen,    (971) 204-0282                           Rubenstein Investor Relations    email:tgwin@calypte.com                  Phone: (212) 843-9337                                             email:tclemensen@rubensteinir.com SOURCE Calypte Biomedical Corporation Theodore R Gwin, Chief Financial Officer, Calypte Biomedical Corporation,+1-971-204-0282, tgwin@calypte.com; Investor, Tim Clemensen, Rubenstein InvestorRelations, +1-212-843-9337, tclemensen@rubensteinir.comhttp://www.prnewswire.com

 

 

 

wenn er ehrliche angaben gemacht hat, dann hängt er mit rund 40.000€ in seinem verderben, verkauft hat er ja angeblich auch nit bei 0,28$...das wird ihn jetzt ganz schön quälen...  

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

 

Das ist doch der letzte dreck diese aktie
 

hast du dir mal überlegt, wie es weitergeht, wenn der kurs weiterhin den bach runter geht?